liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer
GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Södertälje Hospital, Sweden.
Cook County Hospital, Chicago, Illinois, USA.
GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Show others and affiliations
2008 (English)In: Urology, ISSN 0090-4295, E-ISSN 1527-9995, Vol. 72, no 4, 808-812 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES: Dutasteride exerts its beneficial effects on the prostate through suppression of intraprostatic dihydrotestosterone (DHT). The aim of this analysis was to assess the effects of the approved dose of dutasteride (0.5 mg/d), given for 2 weeks to 4 months, on the serum and intraprostatic DHT and testosterone levels in 3 randomized studies.

METHODS: Intraprostatic androgen levels were measured in benign prostatic tissue collected during transurethral resection of the prostate (benign prostatic hyperplasia studies, n = 256) or radical prostatectomy (prostate cancer study, n = 51), performed after 2 weeks, or 1, 3, or 4 months of treatment with dutasteride or with placebo or surgery alone. The serum androgen levels were assessed at the same points during treatment. Data from the control groups were pooled to provide 1 comparison group.

RESULTS: Dutasteride reduced the intraprostatic DHT levels by 83%, 90%, 92%, and 93% after 2 weeks and 1, 3, and 4 months of treatment, respectively, compared with placebo/surgery alone. Dutasteride reduced the serum DHT levels from baseline by 84% at 2 weeks and by approximately 90% at 1, 2, 3, and 4 months compared with a 5.2% increase in the control group. The decrease in DHT levels with dutasteride was accompanied by a reciprocal increase in the serum and intraprostatic testosterone levels. However, the intraprostatic testosterone levels in the dutasteride groups generally remained lower than the intraprostatic DHT levels in the control group.

CONCLUSIONS: The results of our study have shown that dutasteride provides near-maximal suppression of both serum and intraprostatic DHT levels in men with benign prostatic hyperplasia or prostate cancer at all points assessed.

Place, publisher, year, edition, pages
Elsevier, 2008. Vol. 72, no 4, 808-812 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-100194DOI: 10.1016/j.urology.2008.06.032PubMedID: 18718641OAI: diva2:660697
Available from: 2013-10-30 Created: 2013-10-30 Last updated: 2013-11-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Hahn, Robert G.
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 26 hits
ReferencesLink to record
Permanent link

Direct link